Atherosclerosis
Volume 205, Issue 1 , Pages 15-22 , July 2009

The vascular risk associations with migraine: Relation to migraine susceptibility and progression

Received 14 March 2008 ,Revised 3 October 2008 ,Accepted 14 October 2008.

References 

  1. Stang P, Sternfeld B, Sidney S. Migraine headache in a prepaid health plan: ascertainment, demographics, physiological and behavioral factors. Headache. 1996;36:69–76
  2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–657
  3. Horev A, Wirguin I, Lantsberg L, Ifergane G. A high incidence of migraine with aura among morbidly obese women. Headache. 2005;45(7):936–938
  4. Rasmussen BK. Epidemiology of headache. Cephalgia. 2001;21:774–777
  5. Russell MB, Olesen J. Increased familial risk and evidence generic factor in migraine. BMJ. 1995;311(7004):541–544
  6. Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med. 2002;346:257–270
  7. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in migraine model. Nat Med. 2002;8(2):136–142
  8. Tatemichi TK, Mohr JP. Migraine and stroke. In:  Barnett HJM,  Mohr JP,  Stein BM editor. Stroke: pathophysiology diagnosis and management. vol. 2:New York: Churchill Livingstone; 1989;p. 845–868
  9. Welch KM, Brandes AW, Salerno L, Brandes JL. C-reactive protein may be increased in migraine patients who present with complex clinical features. Headache. 2006;46:197–199
  10. Vanmolkot FH, de Hoon JN. Increased C-reactive protein in young adult patients with migraine. Cephalgia. 2007;27:843–846
  11. Munno I, Marinaro M, Bassi A, et al. Immunological aspects in migraine: increased IL-10 plasma levels during attack. Headache. 2001;41:764–767
  12. Empl M, Sostak P, Riedel M, et al. Decreased sTNF-R1 in migraine patients?. Cephalgia. 2003;23:55–58
  13. Cirillo M, Stellanto D, Lombardi C, De Santo NG, Covelli V. Headache and cardiovascular risk factors: positive association with hypertension. Headache. 1999;39:409–416
  14. Bic Z, Blix GG, Hopp HP, Leslie FM, Schell MJ. The influence of a low fat-diet on incidence and severity of migraine headaches. J Women's Heath Gender-based Med. 1999;8:623–630
  15. Bigal ME, Gironda M, Tepper SJ, et al. Headache prevention outcome and body mass index. Cephalgia. 2006;26:445–450
  16. Rainero I, Limone P, Ferrero M, et al. Insulin sensitivity is impaired in patients with migraine. Cephalgia. 2005;25:593–597
  17. Watson KE, Peters Harmel AL, Matson G. Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance. J Cardiovasc Pharmacol Ther. 2003;8:253–260
  18. Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Lipton RB. Chronic daily headache: identification of factors associated with induction and transformation. Headache. 2002;42:575–581
  19. Lea RA, Ovcaric M, Sundholm J, MacMillan J, Griffiths LR. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMD Med. 2004;2:3–10
  20. Schwaag S, Nabavi DG, Frese A, Husstedt I, Evers S. The association between migraine and juvenile stroke: a case-control study. Headache. 2003;43:90–93
  21. Scher AI, Terwindt GM, Picavet HS, et al. Cardiovascular risk factors in migraine: the GEM population-based study. Neurology. 2005;19:683–692
  22. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet. 1990;336:837–839
  23. de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, van Bortel LM. Cranial and peripheral interictal vascular changes in migraine patients. Cephalalgia. 2003;23:96–104
  24. Yetkin E, Ozisik H, Ozcan C, Aksoy Y, Turhan H. Increased dilator response to nitrate and decreased flow-mediated dilatation in migraineurs. Headache. 2007;47(1):104–110
  25. Nagai T, Tabara Y, Igase M, et al. Migraine is associated with enhanced arterial stiffness. Hypertens Res. 2007;30:577–583
  26. Rose KM, Wong TY, Carson AP, et al. Migraine and retinal microvascular abnormalities: the Atherosclerosis Risk in Communities Study. Neurology. 2007;68(20):1694–1700
  27. Lee ST, Chu K, Jung KH, et al. Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology. 2008;70:1510–1517
  28. Kurth T, Schürks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ. 2008;337:a636
  29. Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology. 2005;64:S9–S15
  30. Choudhuri R, Cui L, Yong C, et al. Cortical spreading depression and gene regulation: relevance to migraine. Ann Neurol. 2002;51:499–506
  31. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev. 1993;5:159–177
  32. Welch KMA. Stroke and migraine—the spectrum of cause and effect. Func Neurol. 2003;18:121–126
  33. Blake GI, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763–771
  34. Munno I, Centonze V, Marinaro M, et al. Cytokines and migraine: increase of IK-5 and IL-4 plasma levels. Headache. 1998;38:465–467
  35. Sarchielli P, Alberti A, Baldi A, et al. Proinflammatory cytokines, adhesion molecules and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache. 2006;46:200–207
  36. Rasmussen BK, Olesen J. Symptomatic and non-symptomatic headaches in a general population. Neurology. 1992;42:1225–1231
  37. Gudmundsson LS, Thorgeirsson G, Sigfusson N, Sigvaldason H, Johannsson M. Migraine patients have lower systolic but higher diastolic blood pressure compared with controls in a population-based study of 21,537 subjects. The Reykjavik Study. Cephalalgia. 2006;26(4):436–444
  38. Agostoni E, Aliprandi A. Migraine and hypertension. Neurol Sci. 2008;29(Suppl. 1):S37–S39
  39. Baldrati A, Bini L, D’Alessandro R, et al. Analysis of outcome predictors of migraine towards chronicity. Cephalgia. 1985;5(S2):195–199
  40. Monastero R, Pipia C, Cefalù AB, et al. Association between plasma lipid levels and migraine in subjects aged > or =50 years: preliminary data from the Zabùt Aging Project. Neurol Sci. 2008;29(Suppl. 1):S179–S181
  41. Glueck CJ, Bates SR. Migraine in children: association with primary and familial dyslipoproteinemias. Pediatrics. 1986;77(3):316–321
  42. Moreau T, Manceau E, Giroud-Baleydier F, Dumas R, Giroud M. Headache in hypothyroidism. Prevalence and outcome under thyroid hormone therapy. Cephalgia. 1998;18:687–689
  43. Harel Z, Gascon G, Riggs S, et al. Supplementation with Omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. J Adolesc Health. 2002;31:154–161
  44. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965
  45. Ikeda U, Shimada K. Statins and monocytes. Lancet. 1999;353:2070
  46. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low-density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res. 1993;2051–2061
  47. Marcus DA. Obesity and the impact of chronic pain. Clin J Pain. 2004;20:186–191
  48. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67(2):252–257
  49. Zeilssen PM, Koppeschaar HP, Lips CJ, Hackeng WH. Calcitonin gene-related peptide in human obesity. Peptides. 1991;12:861–863
  50. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a role in migraine. Cephalgia. 2002;22:54–61
  51. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Report. 2005;5:70–75
  52. Alessi MC, Lijnen HR, Bastelica D, Juhan-Vague I. Adipose tissue and atherothrombosis. Pathophysiol Haemost Throm. 2003;33:290–297
  53. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13:84–89
  54. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Rev. 2005;26:439–451
  55. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem. 2002;277:37487–37491
  56. Touzy RM. Endothelial cell IL-8, a new target for adiponectin: implications in vascular protection. Circ Res. 2005;97:1216–1219
  57. Cai XJ, Li CJ, Chen L, et al. A hypothesis: Adiponectin mediates anti-atherosclerosis via adventitia-AMP-iNOS pathway. Med Hypothesis. 2008;70(5):1044–1047
  58. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003;88:3236–3240
  59. Guldiken B, Guldiken S, Demir M, Turgut N, Tugrul A. Low leptin levels in migraine: a case control study. Headache. 2008;48(7):1103–1107
  60. Considine RV. Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions. Semin Vasc Med. 2005;5(1):15–24
  61. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science. 1996;274:1185–1188
  62. Aiston S, Agius L. Leptin enhances glycogen storage in hepatocytes by inhibition of phosphorylase and exerts an additive effect with insulin. Diabetes. 1999;48:15–20
  63. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord. 2001;25(6):805–810
  64. Martin LJ, Mahaney MC, Almasy L, et al. Leptin's sexual dimorphism results from genotype by sex interactions mediated by testosterone. Obes Res. 2002;10:14–21
  65. Marsters JB, Mortimer MJ, Hay KM. Glucose and diet in the fasting migraineurs. Headache. 1986;26:243–247
  66. McCarthy LC, Hosford DA, Riley JH, et al. Single nucleotide polymorphism (SNP) alleles in the insulin receptor gene (INSR) are associated with migraine. Genomics. 2001;78(3):135–149
  67. Tietjen GE, AL-Qasmi MM, Athanas K, Dafer RM, Khuder DA. Increased von Willbrand factor in migraine. Neurology. 2001;57:334–336
  68. Kowa H, Yasui K, Takeshima T, et al. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk for migraine. Am J Med Genet. 2000;96:762–764
  69. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  70. Kara I, Sazci A, Ergul E, Kaya G, Kilic G. Association of the C677T and A 1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res. 2003;111(1/2):84–90
  71. Puddu P. Homocysteine and risk for atherothrombotic events. Cardiologia. 1999;44:627–631
  72. Evers S, Kock HG, Husstedt IW. Plasma homocysteine levels in primary headaches. In:  Olesen J,  Edivnsson L editor. Headache pathogenesis: monoamines, neuropeptides, purines and nitric oxide. Philadelphia: Lippincott-Raven Publisher; 1997;p. 215–218
  73. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin [5HT] IB/ID agonists inhibits trigeminal cell firing in the cat. Brain. 1997;120:2171–2177
  74. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997;17:2309–2315
  75. Yamamoto M, Hara H, Adachi T. Effects of homocysteine on the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett. 2000;486(2):159–162
  76. Yanagihara T, Swanson JW, Stang PE, et al. In: Migraine and risk of stroke: Proceedings of the Second Congress of Stroke. Washington, DC. 1992;
  77. Buring JE, Hebert P, Romero J, et al. Migraine and subsequent risk of stroke in the physicians’ health study. Arch Neurol. 1995;52:129–134
  78. Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol. 1997;52:129–134
  79. Tietjen GE. The risk of stroke in patients with migraine and implications for migraine management. CNS Drugs. 2005;19:683–692
  80. Swartz RH, Kern RZ. Migraine is associated with magnetic resonance imaging white matter abnormalities: a meta-analysis. Arch Neurol. 2004;291:427–434
  81. Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291:427–434
  82. Chabriat H, Vahedi K, Iba-Zizen MT, et al. Clinical spectrum of CADASIL. A study of 7 families. Lancet. 1995;346:934–939
  83. Ohno K, Isotani E, Hirakawa K. MELAS presenting as migraine complicated by stroke: case report. Neuroradiology. 1997;39:781–784
  84. Wingerchuk DM, Spencer B, Dodick DW, Demaerschalk BM. Migraine with aura is a risk factor for cardiovascular and cerebrovascular disease: a critically appraised topic. Neurologist. 2007;13(4):231–233
  85. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–97.
  86. Feinstein AR. The pretherapeutic classification of comorbidity in chronic disease. J Chron Dis. 1970;23:455–468
  87. Hajjar I, Kotchen TA. Trends in prevalence, prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290(2):199–206
  88. Weissel M. Possible consequences of subclinical hypothyroidism. Acta Med Austriaca. 2003;30(4):93–97
  89. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in a methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Artherioscler Thromb Vasc Biol. 1997;17:569–573
  90. Sliwka U, Harscher S, Diehl RR, et al. Spontaneous oscillations in cerebral blood flow velocity give evidence of different autonomic dysfunctions in various types of headache. Headache. 2001;41:157–163
  91. Paterna S, Di Pasquale P, D’Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol. 2000;43:133–136
  92. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322(7277):19–22
  93. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine: the population-based MRI CAMERA study. Brain. 2005;128:2068–2077
  94. Vanmolkot FH, Van Bortel LM, de Hoon JN. Altered arterial function in migraine of recent onset. Neurology. 2007;68:1563–1570
  95. Moschiano F, D’Amico D, Ciusani E, et al. Coagulation abnormalities in migraine and ischaemic cerebrovascular disease: a link between migraine and ischaemic stroke?. Neurol Sci. 2004;25(Suppl. 3):S126–S128
  96. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens. 2005;18:3S–10S
  97. Farinelli I, Missori S, Martelletti P. Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class. Expert Rev Neurother. 2008;8(9):1347–1354
  98. Bunout D, Garrido A, Suazo M, et al. Effects of supplementation with folic acid and antioxidant vitamins on homocysteine levels and LDL oxidation in coronary patients. Nutrition. 2000;16(2):107–110
  99. Liberopoulos EN, Mikhailidis DP. Could statins be useful in the treatment of patients with migraine. Headache. 2006;46(4):672–675
  100. Day C. Thiaolidinediones: a new class of antidiabetic drugs. Diab Med. 1999;16:179–192

PII: S0021-9150(08)00751-X

doi: 10.1016/j.atherosclerosis.2008.10.016

Atherosclerosis
Volume 205, Issue 1 , Pages 15-22 , July 2009

Article Tools